九典制药(300705) - 300705九典制药投资者关系管理信息20250516

Group 1: Sales Performance - The sales of Loxoprofen Sodium Gel Patch are normal, with rapid growth in sales volume achieved through "price for volume" strategy in the hospital market [2] - The company is increasing investment in the outpatient market, promoting rapid growth in outpatient sales revenue through "Jiuyue" brand building and channel penetration [2] Group 2: Product Development - Currently, five external preparations are on the market: Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, Ketorolac Gel, Lidocaine Double Cardine Cream, and Anti-inflammatory Pain Relief Patch [3] - Expected approvals for 2025 include Lidocaine Gel Patch, Indomethacin Gel Patch, Flurbiprofen Gel Patch, and Loxoprofen Sodium Patch [3] - Future approvals in 2026 are anticipated for Ketoprofen Patch, Flurbiprofen Patch, Clobetasol Soft Ointment, and Diclofenac Diethylamine Emulsion [3] Group 3: Mergers and Acquisitions Strategy - The company will consider multiple directions for mergers and acquisitions, focusing on targets that align with its development strategy, enhance the industrial chain, improve technology, and enrich the product pipeline [4] Group 4: Market Adaptation - Overseas transdermal drug products are widely used for pain relief, hormone replacement, cardiovascular, and neurological diseases, including Fentanyl Patch, Lidocaine Gel Patch, Nitroglycerin Patch, and others [5] Group 5: Production Capacity - The company currently has sufficient production capacity to meet existing demand and has reserved workshop space for future needs [6] - Short-term capacity can be increased by adding new production line equipment, while long-term plans will be developed based on operational needs [6] Group 6: Future Strategic Focus - The company aims to expand sales channels, particularly increasing penetration in the outpatient market and enhancing brand influence [7] - There will be a continued emphasis on R&D to develop new products and enrich the product line [8] - The company will optimize production processes and strengthen cost control mechanisms to ensure efficient operations and good returns for shareholders [8]